Is radiographic progression in modern rheumatoid arthritis trials still a robust outcome? Experience from tofacitinib clinical trials.

Landewé, Robert B M; Connell, Carol A; Bradley, John D; Wilkinson, Bethanie; Gruben, David; Strengholt, Sander; van der Heijde, Désirée

Landewé, Robert B M; Connell, Carol A; Bradley, John D; Wilkinson, Bethanie; Gruben, David; Strengholt, Sander; van der Heijde, Désirée.

Afiliação

Landewé RB; Amsterdam Rheumatology Center, Amsterdam, The Netherlands.
Connell CA; Atrium Medical Center, Heerlen, The Netherlands.
Bradley JD; Pfizer Inc, Groton, CT, USA.
Wilkinson B; Pfizer Inc, Groton, CT, USA.
Gruben D; Pfizer Inc, Groton, CT, USA.
Strengholt S; Pfizer Inc, Groton, CT, USA.
van der Heijde D; Pfizer Inc, Capelle aan den IJssel, The Netherlands. sander.strengholt@pfizer.com.

Arthritis Res Ther ; 18(1): 212, 2016 Sep 23.

Article em En | MEDLINE | ID: mdl-27663201

Palavras-chave

Missing data; Modified total Sharp score; Outlier; Prognostic factors; Radiographic progression; Rheumatoid arthritis; Sensitivity analyses; Tofacitinib

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Clinical_trials / Guideline / Prognostic_studies Idioma: En Revista: Arthritis Res Ther Ano de publicação: 2016 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google